$TBPH
Theravance Biopharma Inc

2024 Q4 Form 10-Q Financial Statement

#000155837024015602 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $16.87M
YoY Change 7.49%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.88M
YoY Change 4.54%
% of Gross Profit
Research & Development $9.268M
YoY Change 11.51%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $27.71M
YoY Change 13.3%
Operating Profit -$10.84M
YoY Change 23.71%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.415M
YoY Change -20.77%
Pretax Income -$10.05M
YoY Change 32.56%
Income Tax $2.646M
% Of Pretax Income
Net Earnings -$12.70M
YoY Change 41.88%
Net Earnings / Revenue -75.28%
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$0.26
COMMON SHARES
Basic Shares Outstanding 49.17M 48.92M
Diluted Shares Outstanding 49.04M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.36M
YoY Change -31.82%
Cash & Equivalents $23.38M
Short-Term Investments $67.98M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $116.5M
YoY Change -27.96%
LONG-TERM ASSETS
Property, Plant & Equipment $7.788M
YoY Change -16.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.467M
YoY Change -25.33%
Total Long-Term Assets $239.6M
YoY Change -4.87%
TOTAL ASSETS
Total Short-Term Assets $116.5M
Total Long-Term Assets $239.6M
Total Assets $356.1M
YoY Change -13.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.454M
YoY Change -38.6%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.44M
YoY Change -7.62%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $4.977M
YoY Change -35.19%
Total Long-Term Liabilities $4.977M
YoY Change -35.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.44M
Total Long-Term Liabilities $4.977M
Total Liabilities $28.41M
YoY Change -14.03%
SHAREHOLDERS EQUITY
Retained Earnings -$950.0M
YoY Change 5.49%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $185.7M
YoY Change
Total Liabilities & Shareholders Equity $356.1M
YoY Change -13.9%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$12.70M
YoY Change 41.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001583107
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49174000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48091000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36033
dei Entity Registrant Name
EntityRegistrantName
THERAVANCE BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1226628
dei Entity Address Address Line1
EntityAddressAddressLine1
C/O Theravance Biopharma US, Inc.
dei Entity Address Address Line2
EntityAddressAddressLine2
901 Gateway Boulevard
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
808-6000
dei Security12b Title
Security12bTitle
Ordinary Share $0.00001 Par Value
dei Trading Symbol
TradingSymbol
TBPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49174296
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23378000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39545000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
67983000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
62881000
CY2024Q3 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
16845000
CY2023Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
17474000
CY2024Q3 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
597000
CY2023Q4 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
2038000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7677000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
11603000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
116480000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
133541000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7788000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9068000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29334000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36287000
CY2024Q3 tbph Future Contingent Milestone And Royalty Assets
FutureContingentMilestoneAndRoyaltyAssets
194200000
CY2023Q4 tbph Future Contingent Milestone And Royalty Assets
FutureContingentMilestoneAndRoyaltyAssets
194200000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
836000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
836000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7467000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8067000
CY2024Q3 us-gaap Assets
Assets
356105000
CY2023Q4 us-gaap Assets
Assets
381999000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1454000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1524000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7842000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6443000
CY2024Q3 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
864000
CY2023Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
2246000
CY2024Q3 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
1379000
CY2023Q4 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
2900000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4196000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3923000
CY2024Q3 tbph Tenant Improvement Payable Current
TenantImprovementPayableCurrent
6490000
CY2023Q4 tbph Tenant Improvement Payable Current
TenantImprovementPayableCurrent
6490000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1210000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1241000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23435000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24767000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40785000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45236000
CY2024Q3 tbph Future Royalty Payment Contingencies
FutureRoyaltyPaymentContingencies
29691000
CY2023Q4 tbph Future Royalty Payment Contingencies
FutureRoyaltyPaymentContingencies
27788000
CY2024Q3 tbph Unrecognized Tax Benefits Total
UnrecognizedTaxBenefitsTotal
71563000
CY2023Q4 tbph Unrecognized Tax Benefits Total
UnrecognizedTaxBenefitsTotal
65294000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4977000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5919000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49174000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48091000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1135599000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1122164000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
50000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-65000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-949995000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-909104000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
185654000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
212995000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
356105000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
381999000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16868000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15693000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45627000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39859000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9268000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8311000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28190000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32308000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16875000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16142000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50673000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54603000
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1562000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
4513000
us-gaap Restructuring Charges
RestructuringCharges
2743000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
27705000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
24453000
us-gaap Operating Expenses
OperatingExpenses
83376000
us-gaap Operating Expenses
OperatingExpenses
89654000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10837000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8760000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37749000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49795000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
630000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
609000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1903000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1727000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1415000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1786000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3977000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7269000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10052000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7583000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35675000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44253000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2646000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1367000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5216000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2430000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12698000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8950000
us-gaap Net Income Loss
NetIncomeLoss
-40891000
us-gaap Net Income Loss
NetIncomeLoss
-46683000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
72000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
61000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
115000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-210000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12626000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8889000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40776000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46893000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49038000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49038000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52361000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52361000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48690000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48690000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57287000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57287000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4963000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6262000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15567000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19547000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
193689000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4963000
CY2024Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
397000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
72000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12698000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
185654000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
212995000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
445000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
375000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15567000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2131000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
115000
us-gaap Net Income Loss
NetIncomeLoss
-40891000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
185654000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
280161000
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
30891000
CY2023Q3 tbph Proceeds Payments From Espp Purchases
ProceedsPaymentsFromEsppPurchases
-1000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6262000
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
512000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
61000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8950000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
246130000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
441800000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
166787000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
445000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19547000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1982000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-210000
us-gaap Net Income Loss
NetIncomeLoss
-46683000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
246130000
us-gaap Net Income Loss
NetIncomeLoss
-40891000
us-gaap Net Income Loss
NetIncomeLoss
-46683000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
1288000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
1609000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
1729000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
1494000
tbph Interest Accretion On Future Royalty Payment Contingencies
InterestAccretionOnFutureRoyaltyPaymentContingencies
1903000
tbph Interest Accretion On Future Royalty Payment Contingencies
InterestAccretionOnFutureRoyaltyPaymentContingencies
1727000
us-gaap Share Based Compensation
ShareBasedCompensation
15567000
us-gaap Share Based Compensation
ShareBasedCompensation
19547000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
129000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1353000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
4513000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3361000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2724000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-984000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-629000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
272000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
-1441000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
121000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-3926000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1315000
tbph Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-634000
tbph Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-173000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-533000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3309000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-38000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
354000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1523000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6657000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-17000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4178000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1329000
tbph Period Increase Decrease Unrecognized Tax Benefits
PeriodIncreaseDecreaseUnrecognizedTaxBenefits
6269000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
43000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1295000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10633000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26143000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
142000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1811000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
103022000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
134534000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
99762000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
31435000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
71377000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1513000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3402000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32020000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
445000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
166787000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
375000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
445000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2131000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1982000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2132000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-168324000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16167000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-226487000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40381000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299008000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24214000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72521000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
CY2023Q3 tbph Tenant Improvement Allowance
TenantImprovementAllowance
6490000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Due to the inherent uncertainty in making estimates, actual results could differ materially from those estimates.</p>
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12698000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8950000
us-gaap Net Income Loss
NetIncomeLoss
-40891000
us-gaap Net Income Loss
NetIncomeLoss
-46683000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49038000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49038000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52361000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52361000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48690000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48690000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57287000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57287000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3587000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3459000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3581000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3972000
tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35
tbph Collaboration Arrangement Maximum Potential Payments Receivable
CollaborationArrangementMaximumPotentialPaymentsReceivable
205000000.0
tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23378000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71685000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
836000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
836000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24214000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72521000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
82589000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
82639000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
89125000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
69000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
89060000
tbph Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
P7M
tbph Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
P2M
CY2024Q3 tbph Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2024Q3 tbph Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
57880000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
69000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
57880000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
69000
CY2024Q3 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2024Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2023Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
71400000
CY2024Q3 us-gaap Business Combination Contingent Consideration Asset
BusinessCombinationContingentConsiderationAsset
194200000
tbph Number Of Asset Groups Identified
NumberOfAssetGroupsIdentified
3
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.097
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1600000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
4500000
CY2024Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
38462
CY2024Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
11.551
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
400000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
31412000
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
10.3544
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
325300000
CY2023Q1 tbph Percentage Of Reduction In Workforce
PercentageOfReductionInWorkforce
0.17
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5200000
CY2024Q3 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
CY2023Q1 tbph Number Of Patents Listed In Orange Book
NumberOfPatentsListedInOrangeBook
5
CY2023Q1 tbph Number Of Patents Listed In Orange Book
NumberOfPatentsListedInOrangeBook
5
CY2024Q4 us-gaap Loss Contingency Number Of Defendants
LossContingencyNumberOfDefendants
3
CY2024Q3 us-gaap Loss Contingency Number Of Defendants
LossContingencyNumberOfDefendants
3
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015602-index-headers.html Edgar Link pending
0001558370-24-015602-index.html Edgar Link pending
0001558370-24-015602.txt Edgar Link pending
0001558370-24-015602-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbph-20240930.xsd Edgar Link pending
tbph-20240930x10q.htm Edgar Link pending
tbph-20240930xex31d1.htm Edgar Link pending
tbph-20240930xex31d2.htm Edgar Link pending
tbph-20240930xex32.htm Edgar Link pending
tbph-20240930_cal.xml Edgar Link unprocessable
tbph-20240930_def.xml Edgar Link unprocessable
tbph-20240930_lab.xml Edgar Link unprocessable
tbph-20240930_pre.xml Edgar Link unprocessable
tbph-20240930x10q_htm.xml Edgar Link completed